Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study

TY - JOUR

T1 - Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study

AU - Rabinowits, Guilherme

N1 - Journal of Clinical Oncology (2021) 39(15_suppl):9547-9547

PY - 2021/1/1

Y1 - 2021/1/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/4143

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -